Please Visit the Conference Details, Including Sponsors and Poster Presentations on
Poster Presentations Are Available on http://www.cdiff2020.com Through January 14th, 2021
Saturday November 14th: 8:00 a.m. – 1:30 p.m. EST
Stuart B. Johnson, MD, FIDSA, DTM&H
Conference Co-Chair & Keynote Speaker
Dr. Johnson, MD, FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic: “Incorporating New Data on fidaxomicin and bezlotoxumab into C. difficile Treatment Guidelines.”
Paul Feuerstadt, MD, FACG
Conference Co-Chair & Keynote Speaker
Dr. Feuerstadt, MD, FACG, is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following the completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency, Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden & Milford, CT
Presentation Topic: “C. Difficile Infection: Foundation for the Conference”
Courtney Jones, Associate Director, Marketing and Communications Rebiotix Inc, A Ferring Company.Development and execution of global marketing and communications strategies, reputation building, and relationship management with Key Opinion Leaders in support of leadership within the microbiome space. Strong focus and responsible for strategic advances for the company’s novel microbiome-based technology platform into new therapeutic areas, supported by strong project management and expertise in the microbiome industry.
Presentation Topic: “Developing Next-Generation Microbiome-Based Therapeutics.”
C. diff. Survivors
C. diff. Survivors join us to share personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes and losses endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives. Alma Muhfeld, Dayle Skelly
Presentation Topic: “C. diff. Survivor’s Journey. “
Dr. L. Clifford McDonald graduated from Northwestern University Medical School, completed his Internal Medicine Residency at Michigan State University and an Infectious Diseases Fellowship at the University of South Alabama, following which he completed a fellowship in Medical Microbiology at Duke University. Past positions have included Associate Investigator at the National Health Research Institutes in Taiwan and Assistant Professor in the Division of Infectious Diseases at the University of Louisville. Dr. McDonald is a former Epidemic Intelligence Service officer and former Chief of the Prevention and Response Branch in the Division of Healthcare Quality Promotion at the Center for Disease Control and Prevention (CDC), where he currently serves as the Senior Advisor for Science and Integrity. He is the author or co-author of over 100 peer-reviewed publications with his main interests in the epidemiology and prevention of healthcare-associated infections, especially Clostridium difficile infections, and the prevention of antimicrobial resistance.
Presentation Topic: “Updates From the CDC.”
Erik R. Dubberke, MD, MSPH
Dr. Dubberke, MD, MSPH is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University. He attended medical school at the University of Illinois at Chicago and did his medicine and infectious diseases training at Barnes-Jewish Hospital/Washington University. He received a Master’s of Science in Public Health from St. Louis University. His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infection (CDI). Dr. Dubberke has over 115 publications and made the Thomson Reuters list of Highly Cited Researchers in 2015 and 2016. He was the lead author for the CDI component of the Society for Healthcare Epidemiology of America (SHEA) Compendium to Prevent Healthcare-Associated Infections and is on the panel updating the SHEA/IDSA CDI clinical guidelines. He has also represented SHEA as a Key Informant for the AHRQ Evidence-based Practice Center C. difficile review and at the Department of Health and Human Services Road Map to Eliminate HAI 2013 Action Plan Conference.
Presentation Topic: “Optimizing Prevention of Hospital-Onset Clostridioides difficile infection.”
David Lyerly, Ph.D. is the co-founder and Chief Science Officer of TECHLAB, Inc. He received his B.S. from UNC-Chapel Hill and his Ph.D. in Microbiology/Immunology from Wake Forest Bowman Gray School of Medicine. He and Dr. Tracy Wilkins founded TECHLAB in 1989. TECHLAB focuses on innovative diagnostic solutions for C. difficile, other enteric diseases, and intestinal inflammation.
Presentation Topic: “Clostridioides difficile Infection (CDI): An Inflammatory Intestinal Disease.”
Teena Chopra, MD, FIDSA – Junior Infection Fighters Program, Co-Director of Infection Prevention Education. Dr. Chopra is a Professor of Medicine in the Division of Infectious Diseases, at Wayne State University and the Corporate Medical Director of Hospital Epidemiology, Infection Prevention, and Antibiotic Stewardship at Detroit Medical Center, Wayne State University. Her research interests include Epidemiology of Healthcare-associated Infections, Infection Prevention Antibiotic Stewardship, and Immunization. Dr. Chopra has published over 70 papers in various journals and book chapters. Additionally, she has independently reviewed over 50 journal articles. Dr. Chopra has a special interest in studying the epidemiology of infections, including Clostridium difficile and Multi-Drug Resistant Organisms.
Presentation Topic: “Introduction to the Junior Infection Fighters Educational Program.”
Dale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. Before his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA), and past chair of the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDS
Presentation Topic: “Non-toxigenic C. difficile Is back.”
Professor Mark Wilcox, MD, FRCPath Dr. Wilcox is the Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health, in England in the UK. He was Director of Infection Prevention, and Control, Doctor and Clinical Director of Pathology at LTHT. Dr. Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare-Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare-Associated Infection & Antimicrobial Resistance. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents.
Presentation Topic: TBA
Caterina Oneto, MD C. diff. Global TeleSupport Program, Co-Director Dr. Caterina Oneto is a Clinical Instructor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine. Dr. Oneto is fluent in Spanish. She graduated with a degree in Medicine and Surgery from the Universidad de Valparaiso in Chile and completed her residency in Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. With expertise in endoscopy, colonoscopy, capsule endoscopy, liver, and pancreatic diseases, Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridioides difficile, and FMT (Fecal Microbiota Transplantation).
Presentation Topic: “Introduction to Global TeleSupport Program & More.”
Sahil Khanna, MD, M.B.B.S
Dr. Khanna, MD, MBBS, is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at the University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. Dr. Khanna has completed a Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes, and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program, and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic: “Microbiome Restoration: Getting One Step Closer Every Day! “
Barbara McGovern, MD
Dr. Barbara McGovern is VP, Medical Affairs of Seres. Dr. McGovern has over 25 years of experience in infectious diseases. Prior to joining Seres, she served as Medical Director in the Medical Affairs Division at AbbVie and helped to launch Viekera Pak for treatment of Hepatitis C virus (HCV) infection. At AbbVie, Dr. McGovern was a recipient of the 2015 President’s Award in recognition of the successful execution of 7 major publications in the New England Journal of Medicine, Lancet, and JAMA. As an academic clinician at Tufts Medical Center, she also authored more than 50 journal articles, editorials, and textbook chapters on HIV and HCV and was an Associate Editor of Clinical Infectious Diseases and a Deputy Editor at Up-To-Date.
Presentation Topic: “ECOSPOR III: A Phase 3 Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of SER-109, an Investigational Microbiome Therapeutic for the Treatment of Patients with Recurrent Clostridioides difficile Infection (rCDI).”
Glenn S. Tillotson, Ph.D., FRSM, FCCP
Dr. Tillotson, Ph.D., FRSM, FCCP has 30+ years of pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management, and global launch programs. Dr. Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, and other antibacterials. Glenn has held several key committee positions at the American College of Chest Physicians; he is on the Scientific Steering Committee for the GTCBio. Annual Summit on Anti-infective Partnering. Currently, Dr. Tillotson has published >140 peer-reviewed manuscripts, presented >270 scientific posters, and is on several journals Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine, and F1000.
Presentation Topic: “It’s a Small World with C. diff. -a One Health Perspective.”
Camilla S. Graham, MD, MPH Camilla S. Graham, MD, MPH is Vice President and Chief Clinical Information Officer at Summit Therapeutics as well as a staff physician at Beth Israel Deaconess Medical Center in Boston, MA and on faculty at Harvard Medical School. For twenty years she has focused on identifying barriers to care and medical, policy, or reimbursement solutions for infectious diseases. At Summit she is identifying ways to improve the support of patients and investigators in Ri-CoDIFy, the global phase 3 studies of ridinilazole for C. difficile treatment, and reduction of recurrence.
Presentation Topic: “Ri-CoDIFy: Summit’s Ridinilazole Phase 3 Trial to Advance the Science in the Treatment of C. difficile and Reduction of Recurrence.”
Maureen Spencer, RN, M.Ed. CIC has been an Infection Preventionist for over 40 years and is board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing a MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The groundbreaking work was published in the Journal of Bone and Joint Surgery, Aug 2010. In 2012 she was selected as one of the “Who’s Who of Infection Prevention” and in 2017 she was recognized as a Fellow of the Association for Professionals in Infection Control and Epidemiology (FAPIC) for her advanced practice in infection prevention and leader within the field.
Presentation Topic: “Engaging Middle School Children In Infection Prevention Through the C Diff Foundation’s Junior Infection Fighters Program.”
S P O N S O R S
We are truly grateful for the participation and sponsorships by the organizations that are continuously researching, developing, and addressing healthcare-associated infections worldwide. Many with a primary focus and goal to prevent, treat, and diagnose a leading HAI; Clostridioides difficile (C. diff., C. difficile, CDI) infections and we applaud their dedication in the C. diff. community.
This Medical Education Program Is Supported by a Pfizer Medical Education Grant
To learn more about the Sponsors, please click on the graphics displayed below. Thank you.
Scientific Posters and Poster Presentations Will Also Be Included In the Conference Program Agenda.
Dr. Edmond Hooker, MD, DrPH
Maureen Spencer, RN, M.Ed., CIC
Dr. David Lyerly, Ph.D.
2020 – AWARDS